Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Product Categories
Product Type
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Explore how neutrophils shape the immune response in health and disease. This poster highlights neutrophil pathogen defense mechanisms, including phagocytosis, degranulation, and NETosis, as well as neutrophil roles in inflammation and NET-associated pathologies.
DOWNLOAD NOWCeftizoxime is a cephalosporin antibiotic.1 Ceftizoxime is active against clinical isolates of the Gram-positive bacteria S. aureus, S. pyogenes, and S. epidermidis (IC50s = 1.56, ≤0.025, and 0.78 µg/ml, respectively), as well as clinical isolates of the Gram-negative bacteria E. coli, K. pneumoniae, and P. mirabilis (IC50s = 0.1, ≤0.025, and ≤0.025 µg/ml, respectively). It is protective against S. aureus, E. coli, P. mirabilis, or P. vulgaris infection in mice (ED50s = 4.03, 0.02, 0.255, and 0.038 mg/kg, respectively).2 Formulations containing ceftizoxime have been used in the treatment of a variety of bacterial infections.
WARNING This product is not for human or veterinary use.
1. Ceftizoxime (FK 749), a new parenteral cephalosporin: In vitro and in vivo antibacterial activities. Antimicrob. Agents Chemother. 16(5), 540-548 (1979).
2. Comparison of antibacterial activity of a new cephalosporin, ceftizoxime (FK 749) with other cephalosporin antibiotics. J. Antibiot. (Tokyo) 32(12), 1319-1327 (1979).